Pamela Freiden

Pamela Freiden

Auto-generated profile, based on publicly available information

Pamela Freiden

Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cell Host & Microbe
Verified
Journal Article
Open access
CLChun-Yang Lin
Chun-Yang Lin
JWJoshua Wolf
Joshua Wolf
DBDavid C. Brice
David C. Brice
YSYilun Sun
Yilun Sun
MLMacauley Locke
Macauley Locke
MMMaureen A. McGargill
Maureen A. McGargill
SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to respiratory distress and death. A major unresolved question is whether prior immunity to endemic, human common cold coronaviruses (hCCCoVs) impacts susceptibility to SARS-CoV-2 infection or immunity following infection and vaccination. Therefore, we analyzed samples from the same individuals before and after SARS-CoV-2 infection or vaccination. We found hCCCoV antibody levels increase after SARS-CoV-2 exposure, demonstrating cross-reactivity. However, a case-control study indicates that baseline hCCCoV antibody levels are not associated with protection against SARS-CoV-2 infection. Rather, higher magnitudes of pre-existing betacoronavirus antibodies correlate with more SARS-CoV-2 antibodies following infection, an indicator of greater disease severity. Additionally, immunization with hCCCoV spike proteins before SARS-CoV-2 immunization impedes the generation of SARS-CoV-2-neutralizing antibodies in mice. Together, these data suggest that pre-existing hCCCoV antibodies hinder SARS-CoV-2 antibody-based immunity following infection and provide insight on how pre-existing coronavirus immunity impacts SARS-CoV-2 infection, which is critical considering emerging variants.

14 April 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Luis Martinez-SobridoLuis Martinez-Sobrido
Luis Martinez-Sobrido
PLPilar Blanco Lobo
Pilar Blanco Lobo
LRLaura Rodriguez
Laura Rodriguez
TFTheresa Fitzgerald
Theresa Fitzgerald
HZHanyuan Zhang
Hanyuan Zhang
SSStacey Schultz-Cherry
Stacey Schultz-Cherry
The continual emergence of novel influenza A strains from non-human hosts requires constant vigilance and the need for ongoing research to identify strains that may pose a human public health risk. Since 1999, canine H3 influenza A viruses (CIVs) have caused many thousands or millions of respiratory infections in dogs in the United States. While no human infections with CIVs have been reported to date, these viruses could pose a zoonotic risk. In these studies, the National Institutes of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) network collaboratively demonstrated that CIVs replicated in some primary human cells and transmitted effectively in mammalian models. While people born after 1970 had little or no pre-existing humoral immunity against CIVs, the viruses were sensitive to existing antivirals and we identified a panel of H3 cross-reactive human monoclonal antibodies (hmAbs) that could have prophylactic and/or therapeutic value. Our data predict these CIVs posed a low risk to humans. Importantly, we showed that the CEIRS network could work together to provide basic research information important for characterizing emerging influenza viruses, although there were valuable lessons learned. The 2009 influenza pandemic was a stark reminder that ongoing vigilance is critical to protect the public from an influenza pandemic. The continual evolution of influenza viruses and emergence from animal reservoirs, leads to the need to quickly identify strains that pose a public health risk. In these studies, members of the National Institutes of Allergy and Infectious Diseases (NIAID) Centers for Excellence in Influenza Research and Surveillance (CEIRS) network worked together to demonstrate that the emerging canine H3 influenza viruses posed a low risk to public health and identified several therapeutic options in the event of an emergence. In addition to providing important new basic research, many lessons were learned that may be important in dealing with any emerging disease outbreak.

5 June 2020 in Viruses
Verified
Journal Article
Open access
PDF file
ADAmy Davis
Amy Davis
VCValerie Cortez
Valerie Cortez
MGMarco Grodzki
Marco Grodzki
RDRonald Dallas
Ronald Dallas
JFJose Amadeo Ferrolino
Jose Amadeo Ferrolino
SSStacey Schultz-Cherry
Stacey Schultz-Cherry
Noroviruses are a leading cause of gastroenteritis worldwide. Although infections in healthy individuals are self-resolving, immunocompromised individuals are at risk for chronic disease and severe complications. Chronic norovirus infections in immunocompromised hosts are often characterized by long-term virus shedding, but it is unclear whether this shed virus remains infectious. We investigated the prevalence, genetic heterogeneity, and temporal aspects of norovirus infections in 1140 patients treated during a 6-year period at a pediatric research hospital. Additionally, we identified 20 patients with chronic infections lasting 37 to >418 days. Using a new human norovirus in vitro assay, we confirmed the continuous shedding of infectious virus for the first time. Shedding lasted longer in male patients and those with diarrheal symptoms. Prolonged shedding of infectious norovirus in immunocompromised hosts can potentially increase the likelihood of transmission, highlighting the importance of isolation precautions to prevent nosocomial infections.
1

1 February 2010 in Viruses
Verified
Journal Article
Open access
PDF file
SBScott A. Brown
Scott A. Brown
SSSherri L. Lynn Surman
Sherri L. Lynn Surman
RSRobert E. Sealy
Robert E. Sealy
BJBart G Jones
Bart G Jones
KSKaren S. Slobod
Karen S. Slobod
JHJulia Hurwitz
Julia Hurwitz
Currently, there are more than 30 million people infected with HIV-1 and thousands more are infected each day. Vaccination is the single most effective mechanism for prevention of viral disease, and after more than 25 years of research, one vaccine has shown somewhat encouraging results in an advanced clinical efficacy trial. A modified intent-to-treat analysis of trial results showed that infection was approximately 30% lower in the vaccine group compared to the placebo group. The vaccine was administered using a heterologous prime-boost regimen in which both target antigens and delivery vehicles were changed during the course of inoculations. Here we examine the complexity of heterologous prime-boost immunizations. We show that the use of different delivery vehicles in prime and boost inoculations can help to avert the inhibitory effects caused by vector-specific immune responses. We also show that the introduction of new antigens into boost inoculations can be advantageous, demonstrating that the effect of ‘original antigenic sin’ is not absolute. Pre-clinical and clinical studies are reviewed, including our own work with a three-vector vaccination regimen using recombinant DNA, virus (Sendai virus or vaccinia virus) and protein. Promising preliminary results suggest that the heterologous prime-boost strategy may possibly provide a foundation for the future prevention of HIV-1 infections in humans.

10 May 2024 in Science Advances
Verified
Journal Article
Open access
VMVictoria Meliopoulos
Victoria Meliopoulos
RHRebekah Honce
Rebekah Honce
BLBrandi Livingston
Brandi Livingston
VHVirginia Hargest
Virginia Hargest
PFPamela Freiden
Pamela Freiden
SSStacey Schultz-Cherry
Stacey Schultz-Cherry
Obesity, and the associated metabolic syndrome, is a risk factor for increased disease severity with a variety of infectious agents, including influenza virus. Yet, the mechanisms are only partially understood. As the number of people, particularly children, living with obesity continues to rise, it is critical to understand the role of host status on disease pathogenesis. In these studies, we use a diet-induced obese ferret model and tools to demonstrate that, like humans, obesity resulted in notable changes to the lung microenvironment, leading to increased clinical disease and viral spread to the lower respiratory tract. The decreased antiviral responses also resulted in obese animals shedding higher infectious virus for a longer period, making them more likely to transmit to contacts. These data suggest that the obese ferret model may be crucial to understanding obesity’s impact on influenza disease severity and community transmission and a key tool for therapeutic and intervention development for this high-risk population.

16 April 2021 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
PJPedro Jimenez-Bluhm
Pedro Jimenez-Bluhm
ASAlejandra Sepulveda
Alejandra Sepulveda
CBCecilia Baumberger
Cecilia Baumberger
FPFrancisca Di Pillo
Francisca Di Pillo
SRSoledad Ruiz
Soledad Ruiz
Christopher Hamilton-WestChristopher Hamilton-West
Christopher Hamilton-West